{
    "doi": "https://doi.org/10.1182/blood.V114.22.48.48",
    "article_title": "Improved Immune Reconstitution After Bortezomib-Based Acute Graft-Versus-Host Disease Prophylaxis for HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Allogeneic Transplantation. ",
    "article_date": "November 20, 2009",
    "session_type": "CLINICAL CARE - ACUTE AND CHRONIC GVHD, INFECTIOUS COMPLICATIONS AND IMMUNE RECONSTITUTION OF TRANSPLANTATION: IMMUNOTHERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION",
    "abstract_text": "Abstract 48 We recently reported on the use of the proteasome-inhibitor bortezomib as a novel strategy to control acute graft-versus-host-disease (GVHD). We evaluated bortezomib, tacrolimus and mini-methotrexate for GVHD prophylaxis after reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) with unrelated donors mismatched at 1-2 HLA loci (-A, -B, -C, -DRB1). The regimen was safe, with zero non-relapse mortality. There was a 13% incidence of grade II-IV acute GVHD. We analyzed immune reconstitution in the bortezomib cohort (n=24) [Bort] vs. i) 8/8 matched-related donor (-A, -B, -C, -DRB1) RIC HSCT cohort (n=96) [MRD]; ii) 8/8 matched-unrelated donor RIC HSCT cohort (n=139) [MUD]; and iii) 1-2 HLA mismatched-unrelated donor RIC HSCT cohort (n=24) [MMUD]. Comparator groups received sirolimus, tacrolimus and mini-methotrexate GVHD prophylaxis. All received fludarabine/busulfan conditioning and G-CSF mobilized adult-donor peripheral blood stem cells. All groups had rapid hematopoietic engraftment and >90% median donor-chimerism by day +45 post-HSCT. They were not different with regards to age (p=0.53), sex (p=0.39) and acute grade II-IV GVHD (p=0.63). There was a difference in the proportion of good-risk disease: [Bort] (46%), [MRD] (21%), [MUD] (14%) and [MMUD] (21%) (p=0.005). Chronic GVHD was also different: [Bort] (41%), [MRD] (39%), [MUD] (53%) and [MMUD] (67%) (p=0.03). Peripheral blood cells incubated with directly conjugated monoclonal antibodies defining distinct lymphocyte populations were analyzed by flow cytometry. Lymphocyte subsets included T (CD3+, CD4+, CD8+) B (CD19+, CD20+) NK (CD56+CD16+) NK-T (CD56+CD3+) and regulatory-T (Treg; CD4+CD25+) cells. Unadjusted analyses revealed no significant differences in B, NK, NK-T or Treg recovery. In contrast, CD3+, CD4+ and CD8+ T-cell reconstitution was significantly higher in the bortezomib group, especially at 3 months post-HSCT.  Phenotype . Month . N . [Bort] median cells/uL (range) . N . [MRD] median cells/uL (range) . N . [MUD] median cells/uL (range) . N . [MMUD] median cells/uL (range) . p-value . CD3+ Pre 21 455 (84, 4363) 36 607 (1, 1551) 67 519 (10, 1698) 10 533 (64, 2622) 0.872  1 22 315 (3, 5888) 84 317 (5, 1692) 123 311 (20, 3742) 18 328 (52, 551) 0.848  3 21 753 (31, 1777) 74 373 (8, 3114) 107 386 (0, 2338) 15 485 (22, 2274) <0.001  6 18 932 (47, 1682) 63 486 (37, 3701) 86 498 (59, 3785) 15 681 (60, 1572) 0.036 CD4+ Pre 21 249 (79, 4320) 36 273 (1, 1043) 67 283 (2, 1265) 10 271 (47, 705) 0.930  1 22 187 (2, 4313) 83 210 (2, 851) 123 193 (7, 1682) 18 179 (15, 471) 0.939  3 21 350 (20, 856) 73 237 (6, 1763) 107 215 (0, 654) 15 323 (5, 896) 0.033  6 18 340 (21, 682) 62 306 (10, 1302) 85 261 (21, 1082) 15 346 (43, 648) 0.274 CD8+ Pre 21 173 (6, 392) 36 207 (1, 970) 67 165 (2, 807) 10 232 (9, 2151) 0.531  1 22 111 (1, 1744) 84 70 (3, 681) 123 81 (3, 1266) 18 94 (14, 293) 0.292  3 21 379 (7, 1208) 74 96 (1, 1281) 107 101 (0, 1661) 15 146 (2, 1762) <0.001  6 18 421 (9, 834) 62 142 (18, 3343) 85 197 (25, 2940) 15 189 (15, 1123) 0.030 Phenotype . Month . N . [Bort] median cells/uL (range) . N . [MRD] median cells/uL (range) . N . [MUD] median cells/uL (range) . N . [MMUD] median cells/uL (range) . p-value . CD3+ Pre 21 455 (84, 4363) 36 607 (1, 1551) 67 519 (10, 1698) 10 533 (64, 2622) 0.872  1 22 315 (3, 5888) 84 317 (5, 1692) 123 311 (20, 3742) 18 328 (52, 551) 0.848  3 21 753 (31, 1777) 74 373 (8, 3114) 107 386 (0, 2338) 15 485 (22, 2274) <0.001  6 18 932 (47, 1682) 63 486 (37, 3701) 86 498 (59, 3785) 15 681 (60, 1572) 0.036 CD4+ Pre 21 249 (79, 4320) 36 273 (1, 1043) 67 283 (2, 1265) 10 271 (47, 705) 0.930  1 22 187 (2, 4313) 83 210 (2, 851) 123 193 (7, 1682) 18 179 (15, 471) 0.939  3 21 350 (20, 856) 73 237 (6, 1763) 107 215 (0, 654) 15 323 (5, 896) 0.033  6 18 340 (21, 682) 62 306 (10, 1302) 85 261 (21, 1082) 15 346 (43, 648) 0.274 CD8+ Pre 21 173 (6, 392) 36 207 (1, 970) 67 165 (2, 807) 10 232 (9, 2151) 0.531  1 22 111 (1, 1744) 84 70 (3, 681) 123 81 (3, 1266) 18 94 (14, 293) 0.292  3 21 379 (7, 1208) 74 96 (1, 1281) 107 101 (0, 1661) 15 146 (2, 1762) <0.001  6 18 421 (9, 834) 62 142 (18, 3343) 85 197 (25, 2940) 15 189 (15, 1123) 0.030 View Large View large Download slide View large Download slide  Close modal T-cell immune reconstitution parameters are improved after HLA-mismatched RIC HSCT and bortezomib-based GVHD prophylaxis. Importantly this can be accomplished with rapid hematopoietic engraftment and without increased GVHD incidence in patients without HLA-matched donors. Disclosures: Off Label Use: bortezomib for GVHD control.",
    "topics": [
        "bortezomib",
        "conditioning (psychology)",
        "donors",
        "graft-versus-host disease, acute",
        "human leukocyte antigens",
        "immune reconstitution",
        "mismatch",
        "transplantation, homologous",
        "graft-versus-host disease",
        "hematopoietic stem cell transplantation"
    ],
    "author_names": [
        "John Koreth, MBBS, DPhil",
        "Kristen E. Stevenson, MS",
        "Haesook T. Kim, PhD",
        "Sean McDonough",
        "Maria I. Herrera, PhD",
        "Carol G. Reynolds",
        "Gorka Murga",
        "Vincent T. Ho, MD",
        "Corey Cutler, MD, MPH",
        "Philippe Armand, MD, PhD",
        "Robert J. Soiffer, MD",
        "Joseph H. Antin, MD",
        "Edwin P. Alyea, III, MD",
        "Jerome Ritz, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "John Koreth, MBBS, DPhil",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Kristen E. Stevenson, MS",
            "author_affiliations": [
                "Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Haesook T. Kim, PhD",
            "author_affiliations": [
                "Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sean McDonough",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria I. Herrera, PhD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carol G. Reynolds",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gorka Murga",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vincent T. Ho, MD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Corey Cutler, MD, MPH",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Philippe Armand, MD, PhD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robert J. Soiffer, MD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joseph H. Antin, MD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Edwin P. Alyea, III, MD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jerome Ritz, MD",
            "author_affiliations": [
                "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-11T13:01:03",
    "is_scraped": "1"
}